Global Subcutaneous Immunoglobulin Market Size Envisaged To Reach USD 33.02 Billion By 2032, With 13.7% CAGR Increase: Polaris Market Research

The global Subcutaneous Immunoglobulin Market size and share is currently valued at USD 10.42 billion in 2023. It is anticipated to generate an estimated revenue of USD 33.02 billion by 2032, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 13.7% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2024-2032. The market is highly competitive owing to the existence of market players with a global presence, including Bio Product Laboratory, Biotest AG, CSL Behring, Grifols and others.

New York, NY, Jan. 29, 2024 (GLOBE NEWSWIRE) — A latest research report [115+] pages with 360-degree visibility, titled “Subcutaneous Immunoglobulin Market Share, Size, Trends, Industry Analysis Report, By Application (Primary Immunodeficiency Disease, Secondary Immunodeficiency Disease); By End Use; By Region; Segment Forecast, 2024- 2032″ published by Polaris Market Research in its research repository.

The global subcutaneous immunoglobulin market size and share is currently valued at USD 10.42 billion in 2023. It is anticipated to generate an estimated revenue of USD 33.02 billion by 2032, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 13.7% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2024-2032.

Market Definition

  • What is Subcutaneous Immunoglobulin? How Big is Subcutaneous Immunoglobulin Market Size?

Immunoglobulins are compact proteins produced by the immune system that safeguard against infection. Immunoglobulin substitution therapy is utilized for patients who possess immune inadequacy and who are powerless to make functional immunoglobulin. The rapidly rising demand for the subcutaneous immunoglobulin market can be attributed to the fact that it is utilized as an option to IVIg for immunoglobulin substitution for a period of over 20 years with inoculations administered into the subcutaneous tissue or thighs or abdomen. SCIg requires more repeated inoculations than IVIg but can be administered as a homespun cure. SCIg is just as productive as IVIg at lessening contamination in children with immune inadequacies.

The subcutaneous immunoglobulin market growth can be attributed to the fact that escalating healthcare disbursement is pushing sizeable development in the market size. The escalated fiscal allegiance to healthcare cooperates with the increasing acquisition of subcutaneous immunoglobulin for curing immunodeficiency illnesses. The market profits from the flexibility of subcutaneous regulation, adding to the wider tendency of customized and patient-pivotal healthcare perspectives. The rise in healthcare disbursement eases pronounced funding in progressive therapies such as subcutaneous immunoglobulin, providing patients with more approachable and productive treatment alternatives and highlighting allegiance to inventive solutions for immunodeficiency illnesses.

Explore the “Global Subcutaneous Immunoglobulin Market” with a Free Sample Copy of the Research Report @

Our Sample Report May Includes:

  • 2032 Updated Report Introduction, Overview, and In-depth industry analysis.
  • 115+ Pages Research Report (Inclusion of Updated Research).
  • Provide Chapter-wise guidance on Requests.
  • 2023 Updated Regional Analysis with Graphical Representation of Size, Share & Trends.
  • Includes Updated List of tables & figures.
  • Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis.

Market’s Key Players:

  • ADMA Biologics
  • Bio Product Laboratory
  • Biotest AG
  • China Biologic Products Holdings, Inc.
  • CSL Behring
  • Emergent BioSolutions
  • Grifols
  • Hansa Biopharma
  • InVivo Biotech Services
  • Kedrion Biopharma
  • Kamada Ltd.
  • Laboratoire français du Fractionnement et des Biotechnologies
  • Octapharma
  • Shenzhen Weiguang Biological Products Co., Ltd.
  • Takeda Pharmaceutical Company

Purchase a Full Detail Report With Complete TOC @

Key Highlights

  • The escalated fiscal allegiance to healthcare cooperates with the increasing acquisition of subcutaneous immunoglobulin for curing immunodeficiency illnesses, which is pushing market expansion.
  • The subcutaneous immunoglobulin market analysis is primarily segmented based on application, end-user, and region.
  • North America dominated the market in 2023

Market Developments

  • Growth Drivers:

Escalation in immunodeficiency illnesses: The market is advancing as immunodeficiency illnesses become more common. Situations such as primary and secondary immunodeficiency maladies are pushing the demand. The subcutaneous immunoglobulin market size is expanding as patients possessing imperiled immune systems need efficient subcutaneous immunoglobulin inoculations for immune system augmentation. Its ease, juxtaposed with conventional intravenous procedures, is bringing about market growth. With a growing consciousness of immunodeficiency illnesses and enhanced diagnostics, the market is expected to encounter an escalating demand for approachable and productive immunoglobulin remedies.

Patient pivotal perspective: A patient pivotal perspective pushes the market growth. It is growingly advocated for curing immunodeficiency illnesses, highlighting patient confrontation. Subcutaneous operation permits appropriate self-management at home, intensifying flexibility and curing conformity. The subcutaneous immunoglobulin market sales are soaring as this movement not only enhances contentment but also cooperates with patient inclination, generating a more comprehensible remedial topography. As the market industry forecast proliferates, sequencing patient pivotal care renders important in molding market ambulation, concentrating on solace and choice of individuals encountering immunoglobulin therapy.

  • Industry Trends:

Technological progressions: Technological advancement is pushing sizeable growth in the market. Inventions in drug conveyance, such as the vesture of inoculation gadgets and autoinjectors, improve conduct and enhance patient comfort and compliance. Manufacturing progressions capitulate extremely refined and dense formulations. Maximizing therapeutic outcomes. Progressive diagnostics and observation techniques sanction customized cure plans and concurrent immunoglobulin level tracing. The developing technological topography is modifying the market, pledging enhanced productivity, availability, and patient results in the cure of immunodeficiency illnesses.

Customized dosing discipline: Welcoming a customized healthcare perspective, customized dosing discipline, and inoculation programs are acquiring distinction, particularly as an answer to patients’ particular requirements. Progressive diagnostic technologies sanction accurate estimation of immunoglobulin levels and immune technique estimation, endorsing the individualization of therapies. This customized perspective not only improves cure productivity but also pushes patient contentment and compliance.

  • Restraints:

High costs: The market encounters a sizeable obstacle in the configuration of escalated prices of cures. The fiscal barricade, circumscribing the cost of commodity and operation tools, obstructs its universal acquisition. Accessibility worries restrict patient acquisition, particularly where insurance participation is deficient. The price element also impacts healthcare donors inclination to recommend more conventional and economic therapies.

Inquire more about this report before purchase @

(Inquire a report quote OR available discount offers to the sales team before purchase.)

Segmentation Overview

  • Primary Immunodeficiency Disease Segment Witnessed a Sharp Rise

Based on application, the primary immunodeficiency disease segment witnessed a sharp rise. Subcutaneous immunoglobulin surface as a patient pivotal remedy for primary immunodeficiency, transfiguring cure ambulation. The subcutaneous immunoglobulin market demand is on the rise as sanctioning home spun management, subcutaneous immunoglobulin permits patients with self-managing alternatives, decreasing the dependence on hospital calls and encouraging reliability. Its flexible cure program presenting tailored dosing disciplines gratify distinct preferences and ways of living. Subcutaneous immunoglobulin guarantees a fixed supply of immunoglobulins, sustaining steady antibody levels and thus cautiously preserving against contaminations. With the slightest comprehensive ramifications, it improves patient satiation, providing a well-sanctioned and attainable option.

  • Hospitals Segment Dominated the Market

Based on end use, the hospital segment dominated the market. Hospitals utilize subcutaneous immunoglobulin to cover varying medical conditions. In curing primary immunodeficiency disorders, subcutaneous immunoglobulin reimburses for deficient antibody production, protecting jeopardized immune systems. The subcutaneous immunoglobulin market trends include neurological conditions such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and subcutaneous immunoglobulin provides earmarked immune distortion in hospital settings. 

Subcutaneous Immunoglobulin Market: Report Scope & Dynamics

Report Attribute Details
Revenue Forecast in 2032 USD 33.02 Billion
Market size value in 2024 USD 11.83 Billion
Expected CAGR Growth 13.7% from 2024 – 2032
Base Year 2023
Forecast Year 2024 – 2032
Top Market Players Bio Product Laboratory, Biotest AG, CSL Behring, Grifols, Laboratoire français du Fractionnement et des Biotechnologies among others
Segments Covered
  • By Application
  • By End Use
  • By Region
Competitive Landscape
  • Subcutaneous Immunoglobulin Market Share Analysis (2023)
  • Company Profiles/Industry participants profiling includes company overview, financial information, product/service benchmarking, and recent developments
Customization Options Customized purchase options are available to meet any research needs. Explore customized purchase options

Browse Press Release: Subcutaneous Immunoglobulin Market Size Worth $33.02 Billion By 2032 | CAGR: 13.7%

Regional Insights

North America: The region held the largest subcutaneous immunoglobulin market share due to technological progressions in prescriptions and conveyance practices improving productivity while escalating consciousness amidst patients’ and healthcare donors’ push market impetus. Escalating healthcare disbursement mirrors the identification of its clinical practicality, and governmental consent to proliferate therapy options. Patient pivotal care encourages SCIG’s ease, stimulating broader acquisition. The aggressive topography includes both entrenched and surfacing players motivating inventions. Partnership propels fact-finding, insurance coverage impacts approach, and the COVID-19 influence highlights its important part in immune-connected situations, underscoring sector workability.

Asia Pacific: The subcutaneous immunoglobulin industry in Asia-Pacific encounters sizeable development, especially in surfacing economies. Escalating healthcare approaches and growing consciousness of immunodeficiency illnesses bring about market proliferation. Asia’s position in medical tourism impacts the industry with patients looking for progressive immunoglobulin therapies.

Browse the Detail Report “Subcutaneous Immunoglobulin Market Share, Size, Trends, Industry Analysis Report, By Application (Primary Immunodeficiency Disease, Secondary Immunodeficiency Disease); By End Use; By Region; Segment Forecast, 2024- 2032” with in-depth TOC:  

For Additional Information OR Media Enquiry, Please Mail At:

Key Questions Addressed in the Report:

  • What is the CAGR expected to be recorded for the subcutaneous immunoglobulin Market?

Ans: The CAGR expected to be recorded for the market is 13.7%.

  • What is the current and estimated market value of the market?

Ans: The current market value is USD 10.42 billion, and the expected market value is 33.02 billion.

  • Which are the major players operating in the industry?

Ans: The major players operating in the industry are ADMA Biologics, Bio Product Laboratory, and Biotest AG.

  • Which segments are covered by the report?

Ans: The segments covered in the report are application, end-use, and region.

Polaris Market Research has segmented the Subcutaneous Immunoglobulin market report based on application, end use, and region:

By Application Outlook

  • Primary Immunodeficiency Disease
  • Secondary Immunodeficiency Disease

By End Use Outlook

  • Clinics
  • Hospitals
  • Homecare
  • Others

By Region Outlook

  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

Browse More Research Reports:

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR’s clientele spread across different enterprises. We at Polaris are obliged to serve PMR’s diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR’s customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR’s customers.


Likhil G

30 Wall Street

8th Floor,

New York City, NY 10005,

United States

Phone: +1-929 297-9727



Follow Us: LinkedIn Twitter


Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. takes no editorial responsibility for the same.